[Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors].
Options for antiretroviral therapy in patients infected with HIV continue to expand as new drugs are integrated into treatment regimens. Nucleoside/nucleotide reverse transcriptase inhibitors (Nt/NRTIs) remain the backbone of highly active antiretroviral therapy (HAART). Although this is the oldest class of antiretrovirals, pharmacokinetic and pharmacodynamic properties have been less studied as compare to protease inhibotors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). The aim of this article is to review the current status of clinical pharmacology onf Nt/NRTIs, highlighting the issues with clinical interest. Therefore, implications of intracellular pharmacokinetics on dosing schedule, potential for drug-drug interaction and pharmacodynamics is discussed.
Bonora
S
S
Clinica di Malattie Infettive, Universita di Torino, Italy.
Calcagno
A
A
Gonzalez de Requena
D
D
Bargiacchi
O
O
Di Perri
G
G
D019380:Anti-HIV Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D001711:Biotransformation; D004334:Drug Administration Schedule; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D007408:Intestinal Absorption; D009705:Nucleosides / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D009711:Nucleotides / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D009705:Nucleosides; D009711:Nucleotides; D018894:Reverse Transcriptase Inhibitors